AI and home monitoring could help diabetes patients see their risks clearly
NCT ID NCT06607497
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether an AI tool that shows patients how their blood sugar control compares to others, combined with home monitoring, can improve risk perception and blood sugar levels in adults with poorly controlled type 2 diabetes. About 360 participants aged 36–65 will be split into three groups: one gets the AI tool plus home monitoring, one gets only the AI tool, and one gets usual care. The goal is to see if these tools help people better understand their risks and take action to improve their health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AI-enabled risk communication tool (PERDICT.AI) and telemonitoring system (PTEC-DM)
What this could lead to
If successful, this approach could help people with type 2 diabetes better understand their personal risks and improve blood sugar control, potentially reducing complications.
What could go wrong
This is a relatively small, early-stage trial focused on behavior and perception, not a direct treatment. The improvements may be modest or not sustained, and results may not apply to all diabetes patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SingHealth Polyclinics
Singapore, Singapore